Advertisement


Pierce K.H. Chow, PhD, MBBS, on Hepatocellular Carcinoma: New Data From the IMbrave050 Trial of Atezolizumab, Bevacizumab, and Active Surveillance

AACR Annual Meeting 2023

Advertisement

Pierce K.H. Chow, PhD, MBBS, of the National Cancer Centre, Singapore and Duke-NUS Medical School, discusses phase III findings showing that, for patients with hepatocellular carcinoma at high risk of disease recurrence, adjuvant therapy with atezolizumab plus bevacizumab after resection or thermal ablation was more effective than active surveillance. According to Dr. Chow, these results could lead to reassessment of surgical resection in this disease. (Abstract CT003)



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The IMbrave050 study is a phase three global study of atezolizumab plus bevacizumab used as adjuvant therapy versus active surveillance in patients who have undergone curative surgical resection and also ablation. The premise of this study is that there was no previous adjuvant therapy that was validated for HCC. And because of that, recurrence rates in HCC are very high, particularly among patients with larger tumors, multiple tumors, vascular invasion, and of course poor tumor differentiation. And so for this trial, we specifically enrolled patients with these poor cancer characteristics in a randomized controlled manner. So four to 12 weeks after surgical resection or ablation, they're randomized to receive either atezolizumab and bevacizumab as adjuvant or to the surveillance arm, the caveat being that if they are on the surveillance arm and they do have a recurrence, they are permitted to cross over to the atezolizumab plus bevacizumab arm, and this was run across the entire world. At the point of randomization, the patients are very well distributed between the two groups. Most of the patients were men. They were around 60 years old. More than 80% of them were from Asian ethnicity, and more than 70% of them were enrolled from Asia outside of Japan. More than 60% had evidence of vascular invasion, and more than 40% of them had poor tumor differentiation. The primary endpoint of the study was recurrence-free survival as assessed by independent review facility, and we adopted a hierarchical analysis approach. So the first interim analysis was triggered when 253 recurrence-free survival events were encountered. And at this first interim analysis, the IMbrave050 met its primary endpoint and became a positive trial and had a hazard ratio of 0.73 and a P value of 0.012. And this was achieved at the median follow up of 17.4 months, and at that time, recurrence-free survival was 78% for patients on atezolizumab plus bevacizumab versus 65% for patients on active surveillance. And when we look at the recurrence rates, it was particularly impressive because patients on atezolizumab and bevacizumab had a one third or 33% decrease in recurrence rate. So at landmark analysis at 12 months, this was 34% versus 20% for the two arms respectively. The adverse events were not different from what we saw in 150, the earlier trial for this therapy. The duration of treatment for patients on the 050 was significantly longer than that for the earlier 150 trial, which was for advanced HCC. So in the 050, for example, patients on atezolizumab had a median duration of treatment of 11.1 months and for bevacizumab it was 11 months. But in spite of this very much longer duration of treatment, we do not see an increase in adverse events for 050 compared to the earlier study. The most important adverse events which were encountered were proteinuria, hypertension, decrease in platelet counts, and also derangements of liver function. So in conclusion, this is the first trial historically to be positive for adjuvant therapy in the phase three setting, and this applied to patients across the major clinical subgroups. The adverse events were as we expected for this drug and the disease. And atezolizumab plus bevacizumab may become the standard of care for patients in terms of adjuvant therapy after curative resection or ablation and may also change clinical indications for surgical resection.

Related Videos

Skin Cancer

Marcus O. Butler, MD, on Uveal Melanoma: Tebentafusp and Evidence of Tumor Response

Marcus O. Butler, MD, of Toronto’s Princess Margaret Cancer Centre, discusses evidence of tumor response in orbital lesions treated with tebentafusp in patients with metastatic uveal melanoma. Tebentafusp is a first-in-class novel bispecific protein, the first therapy to show superior overall survival compared with standard therapy for metastatic uveal melanoma. Based on these study findings, a role for this agent as a neoadjuvant treatment warrants further investigation. (Abstract LB 118/1)

Solid Tumors
Supportive Care

Christina M. Dieli-Conwright, PhD, MPH, on Resistance Exercise as Medicine: Improving Health and Cancer Outcomes

Christina M. Dieli-Conwright, PhD, MPH, of Dana-Farber Cancer Institute, discusses her research on the ways in which postdiagnosis exercise, particularly resistance exercise, can build strength and muscle mass and affect cancer outcomes. She also describes her focus on biomarkers related to body composition, inflammation, metabolic dysregulation, and cognition—all influenced by exercise.

Lung Cancer

John V. Heymach, MD, PhD, on NSCLC: New Data on Durvalumab Plus Chemotherapy From the AEGEAN Trial

John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the AEGEAN trial, which showed that patients with treatment-naive, resectable, non–small cell lung cancer (NSCLC) who received neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response, compared with those who received neoadjuvant chemotherapy alone. (Abstract CT005)

Hepatobiliary Cancer

R. Katie Kelley, MD, on Biliary Tract Cancer: Data From KEYNOTE-966 on Pembrolizumab, Gemcitabine, and Cisplatin

R. Katie Kelley, MD, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses phase III findings of the KEYNOTE-966 study, which showed that adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer. (Abstract CT008)

Solid Tumors

Timothy A. Yap, MD, PhD, on New Findings on Treating Solid Tumors With PARP and ATR Inhibitors

Timothy A. Yap, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses safety and efficacy data on three different PARP inhibitors combined with the ATR inhibitor camonsertib in patients with solid tumors harboring DNA damage response alterations. The findings showed that low-dose intermittent regimens of camonsertib and different PARP inhibitor combinations were safe. In addition, anticancer activity was observed in patients with platinum- and PARP inhibitor–resistant tumors. Patients with late-line ovarian cancer derived the most benefit from therapy. (Abstract CT018)

Advertisement

Advertisement




Advertisement